Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep;66(6):359-363.
doi: 10.1111/ajd.14573. Epub 2025 Jul 15.

Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study

Francisco Javier Melgosa Ramos  1   2 , Sergio Santos Alarcón  3 , Almudena Mateu Puchades  2 , Isabel Belinchón Romero  4 , Gemma Mª Pérez Pastor  5 , Luca Schneller-Pavelescu Apetrei  6 , Francisco Javier Mataix Díaz  7 , Antonio Martorell  8 , Manel Velasco Pastor  9 , José María Ortíz Salvador  5 , Antonio Sahuquillo Torralba  10 , Marta Galarreta Pascual  8 , Jorge Magdaleno Tapial  5
Affiliations
Multicenter Study

Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study

Francisco Javier Melgosa Ramos et al. Australas J Dermatol. 2025 Sep.

Abstract

Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation. After 52 weeks of follow-up, guselkumab achieved sustained clinical improvement in skin and joint symptoms, with no observed cases of cancer progression or recurrence. Two patients developed new malignancies during treatment, but guselkumab was not discontinued. These findings support the use of IL-23 inhibitors as a safe therapeutic option in this complex patient population.

Keywords: cancer; guselkumab; malignancy; psoriasis.

PubMed Disclaimer

References

    1. L. Puig, J. Notario, A. López‐Ferrer, et al., “Recommendations From the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients With Cancer and Psoriasis,” Actas Dermo‐Sifiliográficas 115, no. 7 (2024): T702–T711.
    1. s. Vaengebjerg, l. skov, a. egeberg, and n. loft, “Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta‐Analysis,” JAMA Dermatology 156, no. 4 (2020): 421–429.
    1. L. Mastorino, P. Dapavo, G. Avallone, et al., “Biologic Treatment for Psoriasis in Cancer Patients: Should They Still Be Considered Forbidden?,” Journal of Dermatological Treatment 33, no. 5 (2022): 2495–2502.
    1. X. Lu, “Impact of IL‐12 in Cancer,” Current Cancer Drug Targets 17, no. 8 (2017): 682–697.
    1. T. Gracia Cazaña, C. Riera, A. Giménez Arnau, et al., “Guselkumab for Psoriasis in Patients With Current or Previous Malignancy: A Multicenter Retrospective Study,” JAAD International 14 (2024): 125–132.

Publication types

LinkOut - more resources